- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02163018
HAL-MPE1 First-in-human (HAL-MPE1/0043)
July 9, 2015 updated by: HAL Allergy
A First-in-human, Randomized, Double Blind, Placebo Controlled, Single-centre Study to Assess the Safety and Tolerability of HAL-MPE1 in Patients With Peanut Allergy
Currently, there is no effective causal treatment for peanut allergy.
A chemically modified, aluminium hydroxide adsorbed peanut extract (HAL-MPE1) for subcutaneous administration has been developed.
Results from in vitro and in vivo preclinical studies demonstrate the immunotherapeutic potential of HAL-MPE1.
Therefore, a phase I, single-centre clinical trial has been designed to assess the safety and tolerability of HAL-MPE1 in peanut allergic patients.
Study Overview
Study Type
Interventional
Enrollment (Actual)
17
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Odense, Denmark, DK 5000
- Carsten Bindslev-Jensen
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Signed informed consent.
- Male or female subjects aged 18-65 years.
- A well-documented medical history of systemic reactions after ingestion of peanut
- Positive food challenge at ≤1.5 gram peanut protein ingestion within the last 2 years
- Positive serum specific anti-peanut and Ara h 2 Immunoglobulin E (IgE-test) (>0.7 kiloUnits(kU)/L) within the last 2 years
- Forced expiratory volume at one second (FEV1)>70% of predicted value
Exclusion Criteria:
- Subjects with a history of severe anaphylaxis to peanut with the following symptoms: hypotension, hypoxia, neurological compromise (collapse, loss of consciousness or incontinence) during challenge with peanuts.
- Baseline serum tryptase level >20 µg/l
- Known allergy or known hypersensitivity to (placebo) excipients
- Participation in any interventional study aimed at desensitizing the peanut allergy in the past
- Any specific immunotherapy (SCIT, SLIT or OIT) during the study period
- Severe immune disorders (including auto-immune diseases) and/or diseases requiring immunosuppressive drugs
- Significant active malignancies or any malignant disease within the past 5 years
- Severe uncontrolled diseases that could increase the risk for patients participating in the study, including but not limited to: any severe or unstable lung diseases; endocrine diseases; clinically significant renal or hepatic diseases, or haematological disorders; or severe ongoing symptomatic allergic diseases
- History of cardiovascular disease, uncontrolled hypertension or arrhythmias
- Diseases with a contraindication for the use of adrenaline (e.g. hyperthyroidism, glaucoma)
- Use of systemic steroids within 4 weeks before start of the study and during the study
- Treatment with β-blockers/ACE inhibitors
- Vaccination within one week before start of therapy or during study
- Anti-IgE/anti-Tumor necrosis factor (TNF) therapy or any biologic immunomodulatory therapy within the 6 months prior to inclusion and during the study
- Participation in a clinical study with a new investigational drug within the last 3 months or for a biological within the last 6 months prior to or during the study
- Pregnancy (test performed at screening), lactation or inadequate contraceptive measures for women of child-bearing age (contraceptive measures considered adequate are: intrauterine devices, hormonal contraceptives, such as contraceptive pills, implants, transdermal patches, hormonal vaginal devices or injections with prolonged release)
- Alcohol, drug or medication abuse within the past year
- Any clinically significant abnormal laboratory parameter at screening
- Lack or expected lack of cooperation or compliance
- Severe psychiatric, psychological, or neurological disorders
- Patients who are employees of the sponsor, institution or 1st grade relatives or partners of the investigators
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: HAL-MPE1
Subcutaneous administration of increasing doses of HAL-MPE1.
|
Subcutaneous administration of increasing doses of HAL-MPE1
Other Names:
|
PLACEBO_COMPARATOR: Placebo
Subcutaneous administration of placebo
|
Subcutaneous administration of increasing doses of placebo
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety of a SCIT-treatment with HAL-MPE1 in patients with peanut allergy.
Time Frame: up to 20 weeks
|
|
up to 20 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in serum levels of allergen specific immunoglobulins
Time Frame: before and after 15-20 weeks of treatment
|
before and after 15-20 weeks of treatment
|
Change in basophil histamine release test
Time Frame: before and after 15-20 weeks treatment
|
before and after 15-20 weeks treatment
|
Change in titrated skin prick test
Time Frame: before and after 15-20 weeks of treatment
|
before and after 15-20 weeks of treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Carsten Bindslev-Jensen, Prof. Dr., Hudafdeling I og Allergicentret, Odense Universitetshospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2014
Primary Completion (ACTUAL)
May 1, 2015
Study Completion (ACTUAL)
June 1, 2015
Study Registration Dates
First Submitted
June 5, 2014
First Submitted That Met QC Criteria
June 10, 2014
First Posted (ESTIMATE)
June 13, 2014
Study Record Updates
Last Update Posted (ESTIMATE)
July 10, 2015
Last Update Submitted That Met QC Criteria
July 9, 2015
Last Verified
July 1, 2015
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HAL-MPE1/0043
- 2013-004238-13 (EUDRACT_NUMBER)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peanut Allergy
-
Rima RachidUniversity of MinnesotaRecruitingPeanut Hypersensitivity | Peanut Allergy | Food Allergy | Food Allergy Peanut | Peanut-Induced Anaphylaxis | Allergy, PeanutUnited States
-
Scripps HealthThe Scripps Research InstituteWithdrawnFood Allergy PeanutUnited States
-
Novartis PharmaceuticalsTerminatedAllergy, PeanutUnited States, Germany, Japan, Australia, France, Spain, Denmark, Canada, Italy, Netherlands
-
University of ManitobaThe Hospital for Sick Children; University of British Columbia; McGill UniversityEnrolling by invitationAllergy to Peanut
-
Imperial College LondonUniversity of Sydney; National Institute for Health Research, United KingdomCompletedIgE Mediated Peanut AllergyUnited Kingdom
-
King's College LondonCharite University, Berlin, Germany; University Hospital, Bonn; Institut Curie; Levantine UKNot yet recruitingAllergy;Food | Food Allergy Peanut | Pathways and Sources of Exposure
-
Imperial College LondonUniversity College CorkActive, not recruitingPeanut Hypersensitivity | IgE Mediated Peanut AllergyUnited Kingdom
-
University of RochesterNational Institute of Allergy and Infectious Diseases (NIAID)Not yet recruitingEgg Allergy | Food Allergy Peanut | Food Allergy in Infants | Allergy and Immunology | Peanut and Nut AllergyUnited States
-
National Institute of Allergy and Infectious Diseases...Genentech, Inc.; Novartis Pharmaceuticals; Rho Federal Systems Division, Inc.Active, not recruitingPeanut Allergy | Multi-food AllergyUnited States
-
Scott SichererNational Institute of Allergy and Infectious Diseases (NIAID)CompletedPeanut Allergy | Food AllergyUnited States
Clinical Trials on HAL-MPE1
-
NewLink Genetics CorporationTerminatedCarcinoma, Non-Small-Cell LungUnited States
-
PhotocureCompletedCervical Intraepithelial NeoplasiaNorway, Germany
-
Danderyd HospitalUniversity of TsukubaCompletedStroke | Hemiparesis | Gait, Hemiplegic | Ambulation DifficultySweden
-
Brooks RehabilitationUniversity of FloridaActive, not recruitingSpinal Cord InjuriesUnited States
-
HAL AllergyCompletedRhinitis, Allergic | Rhinoconjunctivitis, AllergicCanada
-
Danderyd HospitalUmeå University; Sahlgrenska University Hospital, Sweden; University of TsukubaTerminatedStroke | Hemiparesis | Ambulation DifficultySweden
-
Hospital PlatóCompletedPain, Postoperative | HemorrhoidsSpain
-
Danderyd HospitalUmeå University; Sahlgrenska University Hospital, Sweden; University of TsukubaCompletedStroke | Hemiparesis | Ambulation DifficultySweden